Systemic Review of Published Reports on Primary Cutaneous Cryptococcosis in Immunocompetent Patients.
Primary cutaneous cryptococcosis (PCC) has been confirmed as a distinct clinical entity with secondary cutaneous cryptococcosis from systematic infection since 2003. Although it has been confirmed as a distinct clinical entity, little has progressed on PCC in immunocompetent hosts compared to their immunocompromised counterpart. We reviewed the literature on cases of PCC in immunocompetent patients from 2004 to 2014, and 21 cases from 16 reports were identified. Males are more likely to develop PCC infections, with a ratio of 17:4 male to female. These patients were found to be almost all senior population except for patients from Asia. Asymptomatic or moderate itching manifesting in a painful nodule is the most common presentation, although there is no typical clinical manifestation recorded. Upper limbs are the most common site of infection, accounting for 71.4 % of all patients. Of the 12 identified isolates, 6 strains are identified as C. neoformans, 5 as C. gattii, and 1 as C.laurentii. Fluconazole was used in 10 cases; however, only 80 % of the 10 cases could confirm that fluconazole was effective in clearing the infections. Interestingly although not approved as a treatment option, Itraconazole was effective in the seven cases it was used to treat cryptococcosis, with a dosage range of 100-400 mg/d and duration from 3 to 6 months. Even though the prognosis of these patients was generally good, more data are need to determine which antifungal azole is the better treatment option and whether primary skin infections could disseminate to systematic infection.
Department of Dermatology and Mycology Center, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Lin
L
Du
Yali
Y
Yang
Julin
J
Gu
Jianghan
J
Chen
Wanqing
W
Liao
Yuanjie
Y
Zhu
D005260:Female; D006801:Humans; D008297:Male; D000367:Age Factors; D000935:Antifungal Agents / Q000627:therapeutic use; D003453:Cryptococcosis / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D003454:Cryptococcus / Q000145:classification / Q000302:isolation & purification; D003881:Dermatomycoses / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000473:pathology; D015725:Fluconazole / Q000627:therapeutic use; D017964:Itraconazole / Q000627:therapeutic use; D012737:Sex Factors; D016896:Treatment Outcome
D000935:Antifungal Agents; D015725:Fluconazole; D017964:Itraconazole